<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE pdf2xml SYSTEM "pdf2xml.dtd">

<pdf2xml producer="poppler" version="23.12.0">
<page number="1" position="absolute" top="0" left="0" height="841" width="595">
	<fontspec id="0" size="8" family="LEIMEB+URWPalladioL-Ital" color="#000000"/>
	<fontspec id="1" size="8" family="OTBSVX+URWPalladioL" color="#000000"/>
	<fontspec id="2" size="8" family="PYKWEA+URWPalladioL-Roma" color="#000000"/>
	<fontspec id="3" size="8" family="ABCDEE+Palatino Linotype,Italic" color="#000000"/>
	<fontspec id="4" size="8" family="ABCDEE+Palatino Linotype,Bold" color="#000000"/>
	<fontspec id="5" size="8" family="ABCDEE+Palatino Linotype" color="#000000"/>
	<fontspec id="6" size="9" family="Times New Roman" color="#000000"/>
	<fontspec id="7" size="12" family="ABCDEE+Palatino Linotype" color="#000000"/>
	<fontspec id="8" size="9" family="ABCDEE+Palatino Linotype,Bold" color="#000000"/>
	<fontspec id="9" size="9" family="ABCDEE+Palatino Linotype" color="#000000"/>
	<fontspec id="10" size="9" family="ABCDEE+Palatino Linotype,Italic" color="#000000"/>
	<fontspec id="11" size="8" family="ABCDEE+Palatino Linotype,BoldItalic" color="#000000"/>
	<fontspec id="12" size="10" family="ABCDEE+Palatino Linotype,Bold" color="#000000"/>
	<fontspec id="13" size="10" family="ABCDEE+Palatino Linotype" color="#000000"/>
	<fontspec id="14" size="10" family="ABCDEE+Palatino Linotype,Italic" color="#000000"/>
	<fontspec id="15" size="9" family="OTBSVX+URWPalladioL" color="#000000"/>
	<fontspec id="16" size="9" family="PYKWEA+URWPalladioL-Roma" color="#000000"/>
	<fontspec id="17" size="9" family="LEIMEB+URWPalladioL-Ital" color="#000000"/>
	<fontspec id="18" size="10" family="OTBSVX+URWPalladioL" color="#000000"/>
	<fontspec id="19" size="10" family="PYKWEA+URWPalladioL-Roma" color="#000000"/>
	<fontspec id="20" size="10" family="LEIMEB+URWPalladioL-Ital" color="#000000"/>
	<fontspec id="21" size="10" family="PYKWEA+URWPalladioL-Roma" color="#0775b7"/>
<text top="57" left="76" width="33" height="8" font="0">Proteomes</text>
<text top="57" left="111" width="16" height="8" font="1"><b>2017</b></text>
<text top="57" left="127" width="2" height="8" font="2">,</text>
<text top="57" left="131" width="4" height="8" font="0">5</text>
<text top="57" left="135" width="12" height="8" font="2">, 24</text>
<text top="57" left="496" width="23" height="8" font="2">8 of 11</text>
<text top="68" left="77" width="35" height="8" font="3"><i>Proteomes </i></text>
<text top="68" left="113" width="16" height="8" font="4"><b>2017</b></text>
<text top="68" left="129" width="4" height="8" font="5">, </text>
<text top="68" left="133" width="8" height="8" font="3"><i>22</i></text>
<text top="68" left="141" width="18" height="8" font="5">, 24   </text>
<text top="68" left="497" width="25" height="8" font="5">8 of 12 </text>
<text top="805" left="77" width="2" height="8" font="6"> </text>
<text top="273" left="445" width="3" height="12" font="7"> </text>
<text top="293" left="99" width="37" height="9" font="8"><b>Figure  3.</b></text>
<text top="293" left="135" width="365" height="9" font="9">  Boxplots  of  S/CO  values  of  CagA,  VacA  m1  and  HP0231  in  different  subgroups  of  HP </text>
<text top="306" left="99" width="402" height="9" font="9">positive samples. Every box represents the interquartile range and the horizontal line inside the box </text>
<text top="319" left="99" width="402" height="9" font="9">is the median. Whiskers show the 5th and the 95th percentiles. Outliers are plotted as circles. S/CO </text>
<text top="332" left="99" width="328" height="9" font="9">values  of  IgG  responses  towards  CagA,  VacA  m1,  and  HP0231  are  shown  for </text>
<text top="332" left="428" width="35" height="9" font="10"><i>H.  pylori</i></text>
<text top="332" left="463" width="38" height="9" font="9">  positive </text>
<text top="345" left="99" width="98" height="9" font="9">asymptomatic samples (</text>
<text top="345" left="197" width="5" height="9" font="10"><i>n</i></text>
<text top="345" left="202" width="81" height="9" font="9"> = 66; white boxes), </text>
<text top="345" left="283" width="34" height="9" font="10"><i>H. pylori</i></text>
<text top="345" left="317" width="112" height="9" font="9"> positive atrophic samples (</text>
<text top="345" left="429" width="5" height="9" font="10"><i>n</i></text>
<text top="345" left="434" width="67" height="9" font="9"> = 18; light gray </text>
<text top="358" left="99" width="30" height="9" font="9">boxes), </text>
<text top="358" left="128" width="33" height="9" font="10"><i>H. pylori</i></text>
<text top="358" left="161" width="157" height="9" font="9"> positive intestinal metaplasia samples (</text>
<text top="358" left="318" width="5" height="9" font="10"><i>n</i></text>
<text top="358" left="323" width="87" height="9" font="9"> = 41; gray boxes) and </text>
<text top="358" left="410" width="33" height="9" font="10"><i>H. pylori</i></text>
<text top="358" left="443" width="58" height="9" font="9"> positive ulcer </text>
<text top="371" left="99" width="38" height="9" font="9">samples (</text>
<text top="371" left="136" width="5" height="9" font="10"><i>n</i></text>
<text top="371" left="141" width="94" height="9" font="9"> = 14; dark gray boxes). </text>
<text top="396" left="153" width="33" height="9" font="8"><b>Table 3.</b></text>
<text top="396" left="186" width="260" height="9" font="9"> Odds ratios and confidence intervals of different patient groups. </text>
<text top="415" left="193" width="2" height="8" font="5"> </text>
<text top="415" left="319" width="2" height="8" font="4"><b> </b></text>
<text top="415" left="352" width="46" height="8" font="4"><b>Risk Factor (</b></text>
<text top="415" left="397" width="4" height="8" font="11"><i><b>n</b></i></text>
<text top="415" left="402" width="36" height="8" font="4"><b> Patients) </b></text>
<text top="415" left="458" width="2" height="8" font="4"><b> </b></text>
<text top="415" left="489" width="2" height="8" font="4"><b> </b></text>
<text top="426" left="193" width="2" height="8" font="5"> </text>
<text top="426" left="319" width="2" height="8" font="4"><b> </b></text>
<text top="426" left="348" width="35" height="8" font="4"><b>Diseased </b></text>
<text top="426" left="394" width="49" height="8" font="4"><b>not Diseased </b></text>
<text top="426" left="458" width="2" height="8" font="4"><b> </b></text>
<text top="426" left="489" width="2" height="8" font="4"><b> </b></text>
<text top="437" left="179" width="30" height="8" font="4"><b>Groups </b></text>
<text top="437" left="304" width="32" height="8" font="4"><b>Antigen </b></text>
<text top="437" left="347" width="14" height="8" font="4"><b>yes </b></text>
<text top="437" left="372" width="11" height="8" font="4"><b>no </b></text>
<text top="437" left="398" width="14" height="8" font="4"><b>yes </b></text>
<text top="437" left="428" width="11" height="8" font="4"><b>no </b></text>
<text top="437" left="452" width="14" height="8" font="4"><b>OR </b></text>
<text top="437" left="476" width="28" height="8" font="4"><b>95% CI </b></text>
<text top="459" left="118" width="55" height="8" font="5">asymptomatic (</text>
<text top="459" left="173" width="4" height="8" font="3"><i>n</i></text>
<text top="459" left="178" width="67" height="8" font="5"> = 17) vs. atrophic (</text>
<text top="459" left="244" width="4" height="8" font="3"><i>n</i></text>
<text top="459" left="249" width="21" height="8" font="5"> = 17) </text>
<text top="448" left="309" width="22" height="8" font="5">CagA </text>
<text top="448" left="349" width="10" height="8" font="5">14 </text>
<text top="448" left="375" width="6" height="8" font="5">3 </text>
<text top="448" left="402" width="6" height="8" font="5">8 </text>
<text top="448" left="431" width="6" height="8" font="5">9 </text>
<text top="448" left="453" width="12" height="8" font="5">5.3 </text>
<text top="448" left="475" width="30" height="8" font="5">1.1–25.2 </text>
<text top="459" left="303" width="35" height="8" font="5">VacA m1 </text>
<text top="459" left="351" width="6" height="8" font="5">8 </text>
<text top="459" left="375" width="6" height="8" font="5">9 </text>
<text top="459" left="402" width="6" height="8" font="5">2 </text>
<text top="459" left="429" width="10" height="8" font="5">15 </text>
<text top="459" left="453" width="12" height="8" font="5">6.7 </text>
<text top="459" left="475" width="30" height="8" font="5">1.2–38.6 </text>
<text top="470" left="305" width="29" height="8" font="5">HP0231 </text>
<text top="470" left="349" width="10" height="8" font="5">10 </text>
<text top="470" left="375" width="6" height="8" font="5">7 </text>
<text top="470" left="402" width="6" height="8" font="5">6 </text>
<text top="470" left="429" width="10" height="8" font="5">11 </text>
<text top="470" left="453" width="12" height="8" font="5">2.6 </text>
<text top="470" left="475" width="30" height="8" font="5">0.7–10.5 </text>
<text top="492" left="96" width="55" height="8" font="5">asymptomatic (</text>
<text top="492" left="151" width="4" height="8" font="3"><i>n</i></text>
<text top="492" left="156" width="110" height="8" font="5"> = 40) vs. intestinal metaplasia (</text>
<text top="492" left="266" width="4" height="8" font="3"><i>n</i></text>
<text top="492" left="270" width="21" height="8" font="5"> = 40) </text>
<text top="481" left="309" width="22" height="8" font="5">CagA </text>
<text top="481" left="349" width="10" height="8" font="5">36 </text>
<text top="481" left="375" width="6" height="8" font="5">4 </text>
<text top="481" left="400" width="10" height="8" font="5">24 </text>
<text top="481" left="429" width="10" height="8" font="5">16 </text>
<text top="481" left="453" width="12" height="8" font="5">6.0 </text>
<text top="481" left="475" width="30" height="8" font="5">1.8–20.2 </text>
<text top="492" left="303" width="35" height="8" font="5">VacA m1 </text>
<text top="492" left="351" width="6" height="8" font="5">9 </text>
<text top="492" left="373" width="10" height="8" font="5">31 </text>
<text top="492" left="402" width="6" height="8" font="5">6 </text>
<text top="492" left="429" width="10" height="8" font="5">34 </text>
<text top="492" left="453" width="12" height="8" font="5">1.7 </text>
<text top="492" left="477" width="26" height="8" font="5">0.5–5.2 </text>
<text top="503" left="305" width="29" height="8" font="5">HP0231 </text>
<text top="503" left="349" width="10" height="8" font="5">14 </text>
<text top="503" left="373" width="10" height="8" font="5">26 </text>
<text top="503" left="400" width="10" height="8" font="5">19 </text>
<text top="503" left="429" width="10" height="8" font="5">21 </text>
<text top="503" left="453" width="12" height="8" font="5">0.6 </text>
<text top="503" left="477" width="26" height="8" font="5">0.2–1.5 </text>
<text top="525" left="94" width="55" height="8" font="5">asymptomatic (</text>
<text top="525" left="149" width="4" height="8" font="3"><i>n</i></text>
<text top="525" left="153" width="116" height="8" font="5"> = 51) vs. premalignant changes (</text>
<text top="525" left="269" width="4" height="8" font="3"><i>n</i></text>
<text top="525" left="273" width="21" height="8" font="5"> = 57) </text>
<text top="514" left="309" width="22" height="8" font="5">CagA </text>
<text top="514" left="349" width="10" height="8" font="5">50 </text>
<text top="514" left="375" width="6" height="8" font="5">7 </text>
<text top="514" left="400" width="10" height="8" font="5">28 </text>
<text top="514" left="429" width="10" height="8" font="5">23 </text>
<text top="514" left="453" width="12" height="8" font="5">5.9 </text>
<text top="514" left="475" width="30" height="8" font="5">2.2–15.4 </text>
<text top="525" left="303" width="35" height="8" font="5">VacA m1 </text>
<text top="525" left="349" width="10" height="8" font="5">17 </text>
<text top="525" left="373" width="10" height="8" font="5">40 </text>
<text top="525" left="402" width="6" height="8" font="5">8 </text>
<text top="525" left="429" width="10" height="8" font="5">43 </text>
<text top="525" left="453" width="12" height="8" font="5">2.3 </text>
<text top="525" left="477" width="26" height="8" font="5">0.9–5.9 </text>
<text top="536" left="305" width="29" height="8" font="5">HP0231 </text>
<text top="536" left="349" width="10" height="8" font="5">24 </text>
<text top="536" left="373" width="10" height="8" font="5">33 </text>
<text top="536" left="400" width="10" height="8" font="5">24 </text>
<text top="536" left="429" width="10" height="8" font="5">27 </text>
<text top="536" left="453" width="12" height="8" font="5">0.8 </text>
<text top="536" left="477" width="26" height="8" font="5">0.4–1.8 </text>
<text top="558" left="124" width="55" height="8" font="5">asymptomatic (</text>
<text top="558" left="179" width="4" height="8" font="3"><i>n</i></text>
<text top="558" left="183" width="55" height="8" font="5"> = 14) vs. ulcer (</text>
<text top="558" left="238" width="4" height="8" font="3"><i>n</i></text>
<text top="558" left="243" width="21" height="8" font="5"> = 14) </text>
<text top="547" left="309" width="22" height="8" font="5">CagA </text>
<text top="547" left="349" width="10" height="8" font="5">10 </text>
<text top="547" left="375" width="6" height="8" font="5">4 </text>
<text top="547" left="402" width="6" height="8" font="5">7 </text>
<text top="547" left="431" width="6" height="8" font="5">7 </text>
<text top="547" left="453" width="12" height="8" font="5">2.5 </text>
<text top="547" left="475" width="30" height="8" font="5">0.5–11.9 </text>
<text top="558" left="303" width="35" height="8" font="5">VacA m1 </text>
<text top="558" left="351" width="6" height="8" font="5">3 </text>
<text top="558" left="373" width="10" height="8" font="5">11 </text>
<text top="558" left="400" width="10" height="8" font="5">12 </text>
<text top="558" left="431" width="6" height="8" font="5">2 </text>
<text top="558" left="453" width="12" height="8" font="5">1.6 </text>
<text top="558" left="475" width="30" height="8" font="5">0.2–11.7 </text>
<text top="569" left="305" width="29" height="8" font="5">HP0231 </text>
<text top="569" left="351" width="6" height="8" font="5">5 </text>
<text top="569" left="375" width="6" height="8" font="5">9 </text>
<text top="569" left="402" width="6" height="8" font="5">7 </text>
<text top="569" left="431" width="6" height="8" font="5">7 </text>
<text top="569" left="453" width="12" height="8" font="5">0.6 </text>
<text top="569" left="477" width="26" height="8" font="5">0.1–2.5 </text>
<text top="582" left="99" width="402" height="9" font="9">The samples of the compared groups were matched for age and gender. Th<a href="">e atroph</a>ic and intestinal </text>
<text top="595" left="99" width="402" height="9" font="9">metaplasia  status  were  taken  together  as  “premalignant  changes”  and  also  compared  to  the </text>
<text top="608" left="99" width="132" height="9" font="9">asymptomatic group of samples. </text>
<text top="632" left="77" width="63" height="10" font="12"><b>4. Discussion </b></text>
<text top="652" left="99" width="423" height="10" font="13">During  assay  development,  the  incubation  times  for  the  samples  and  the  detection  antibody </text>
<text top="665" left="77" width="445" height="10" font="13">were  optimized  in  order  to  keep  them  as  short  as  possible,  without  a  loss  of  sensitivity.  The </text>
<text top="679" left="77" width="445" height="10" font="13">microfluidic system allows a short assay protocol, with a 35 min assay incubation time in total. This </text>
<text top="692" left="77" width="445" height="10" font="13">is less than one third of the assay time needed in other commercially available immunoblot systems. </text>
<text top="706" left="77" width="445" height="10" font="13">Besides  a  high  technical  assay  precision,  very  good  results  were  achieved  for  specificity  and </text>
<text top="719" left="77" width="184" height="10" font="13">sensitivity  of  the  selected  antigens.  The </text>
<text top="719" left="263" width="39" height="10" font="14"><i>H.  pylori</i></text>
<text top="719" left="302" width="220" height="10" font="13">  lysate  showed  the  best  sensitivity  (99.3%)  and </text>
<text top="732" left="77" width="445" height="10" font="13">specificity  (100%)  in  this  study,  and  the  overall  performance  was  better  compared  to  other </text>
<text top="746" left="77" width="277" height="10" font="13">commercial tests (claimed in the test manual), which also use a </text>
<text top="746" left="354" width="36" height="10" font="14"><i>H. pylori</i></text>
<text top="746" left="391" width="131" height="10" font="13"> lysate, e.g., anti-Helicobacter </text>
<text top="759" left="77" width="445" height="10" font="13">pylori IgG (Orgentec Diagnostika GmbH, Main, Germany) or Helico Blot 2.1 (MP Biomedicals Asia </text>
<text top="773" left="77" width="445" height="10" font="13">Pacific  Pte  Ltd.,  the  Cavendish  Singapore  Science  Park,  Singapore).  In  comparison  to  another </text>
<text top="786" left="77" width="445" height="10" font="13">multiplex serological assay by Michel et al. [22], which showed 89% sensitivity and 82% specificity, </text>
<text top="295" left="98" width="35" height="9" font="15"><b>Figure 3.</b></text>
<text top="295" left="135" width="362" height="9" font="16">Boxplots of S/CO values of CagA, VacA m1 and HP0231 in different subgroups of HP positive</text>
<text top="307" left="98" width="400" height="9" font="16">samples. Every box represents the interquartile range and the horizontal line inside the box is the</text>
<text top="320" left="98" width="400" height="9" font="16">median. Whiskers show the 5th and the 95th percentiles. Outliers are plotted as circles. S/CO values of</text>
<text top="333" left="98" width="270" height="9" font="16">IgG responses towards CagA, VacA m1, and HP0231 are shown for</text>
<text top="333" left="370" width="33" height="9" font="17">H. pylori</text>
<text top="333" left="406" width="92" height="9" font="16">positive asymptomatic</text>
<text top="346" left="98" width="38" height="9" font="16">samples (</text>
<text top="346" left="136" width="5" height="9" font="17">n</text>
<text top="346" left="143" width="75" height="9" font="16">= 66; white boxes),</text>
<text top="346" left="220" width="33" height="9" font="17">H. pylori</text>
<text top="346" left="256" width="108" height="9" font="16">positive atrophic samples (</text>
<text top="346" left="364" width="5" height="9" font="17">n</text>
<text top="346" left="371" width="91" height="9" font="16">= 18; light gray boxes),</text>
<text top="346" left="464" width="33" height="9" font="17">H. pylori</text>
<text top="359" left="98" width="154" height="9" font="16">positive intestinal metaplasia samples (</text>
<text top="359" left="252" width="5" height="9" font="17">n</text>
<text top="359" left="259" width="84" height="9" font="16">= 41; gray boxes) and</text>
<text top="359" left="345" width="33" height="9" font="17">H. pylori</text>
<text top="359" left="380" width="93" height="9" font="16">positive ulcer samples (</text>
<text top="359" left="473" width="5" height="9" font="17">n</text>
<text top="359" left="480" width="19" height="9" font="16">= 14;</text>
<text top="372" left="98" width="69" height="9" font="16">dark gray boxes).</text>
<text top="398" left="77" width="61" height="10" font="18"><b>4. Discussion</b></text>
<text top="417" left="98" width="421" height="10" font="19">During assay development, the incubation times for the samples and the detection antibody were</text>
<text top="431" left="77" width="442" height="10" font="19">optimized in order to keep them as short as possible, without a loss of sensitivity. The microfluidic</text>
<text top="444" left="77" width="442" height="10" font="19">system allows a short assay protocol, with a 35 min assay incubation time in total. This is less than</text>
<text top="458" left="77" width="442" height="10" font="19">one third of the assay time needed in other commercially available immunoblot systems. Besides</text>
<text top="471" left="77" width="442" height="10" font="19">a high technical assay precision, very good results were achieved for specificity and sensitivity of</text>
<text top="485" left="77" width="115" height="10" font="19">the selected antigens. The</text>
<text top="485" left="194" width="37" height="10" font="20">H. pylori</text>
<text top="485" left="234" width="286" height="10" font="19">lysate showed the best sensitivity (99.3%) and specificity (100%)</text>
<text top="498" left="77" width="442" height="10" font="19">in this study, and the overall performance was better compared to other commercial tests (claimed</text>
<text top="512" left="77" width="168" height="10" font="19">in the test manual), which also use a</text>
<text top="512" left="248" width="38" height="10" font="20">H. pylori</text>
<text top="512" left="289" width="229" height="10" font="19">lysate, e.g., anti-Helicobacter pylori IgG (Orgentec</text>
<text top="526" left="77" width="442" height="10" font="19">Diagnostika GmbH, Main, Germany) or Helico Blot 2.1 (MP Biomedicals Asia Pacific Pte Ltd., the</text>
<text top="539" left="77" width="443" height="10" font="19">Cavendish Singapore Science Park, Singapore). In comparison to another multiplex serological assay</text>
<text top="553" left="77" width="72" height="10" font="19">by Michel et al. <a href="">[</a></text>
<text top="553" left="149" width="10" height="10" font="21"><a href="">22</a></text>
<text top="553" left="159" width="360" height="10" font="19"><a href="">], </a>which showed 89% sensitivity and 82% specificity, we received higher sensitivity</text>
<text top="566" left="77" width="142" height="10" font="19">and specificity for FliD and the</text>
<text top="566" left="222" width="38" height="10" font="20">H. pylori</text>
<text top="566" left="263" width="256" height="10" font="19">lysate. The other antigens for sample classification used</text>
<text top="580" left="77" width="325" height="10" font="19">in our assay yielded lower sensitivity (82.0–87.1%) than Michel et al. <a href="">[</a></text>
<text top="580" left="402" width="10" height="10" font="21"><a href="">22</a></text>
<text top="580" left="412" width="107" height="10" font="19"><a href="">], </a>but higher specificity</text>
<text top="593" left="76" width="292" height="10" font="19">(95.2–97.4%). The clinical classification as positive or negative for an</text>
<text top="593" left="370" width="36" height="10" font="20">H. pylori</text>
<text top="593" left="408" width="111" height="10" font="19">infection of these samples</text>
<text top="607" left="76" width="444" height="10" font="19">was determined by Warthin–Starry silver stain, after taking a biopsy, and not by serology. Therefore,</text>
<text top="620" left="77" width="442" height="10" font="19">a comparison of sensitivity and specificity of our assay with a non-invasive clinical classification</text>
<text top="634" left="77" width="403" height="10" font="19">method (e.g., ELISA) was not possible. However, sensitivity and specificity of the different</text>
<text top="634" left="482" width="37" height="10" font="20">H. pylori</text>
<text top="647" left="77" width="442" height="10" font="19">antigens and the lysate in our assay should be confirmed with another set of samples positive and</text>
<text top="661" left="77" width="53" height="10" font="19">negative for</text>
<text top="661" left="132" width="37" height="10" font="20">H. pylori</text>
<text top="661" left="168" width="2" height="10" font="19">.</text>
<text top="674" left="98" width="340" height="10" font="19">FliD showed the best sensitivity (95.7%) as a single antigen, but also, 2 of 63</text>
<text top="674" left="440" width="37" height="10" font="20">H. pylori</text>
<text top="674" left="480" width="38" height="10" font="19">negative</text>
<text top="688" left="77" width="442" height="10" font="19">samples were reactive to FliD, giving the specificity of 96.8%. Exactly these two samples showed also</text>
<text top="701" left="77" width="124" height="10" font="19">reactivity towards one other</text>
<text top="701" left="203" width="36" height="10" font="20">H. pylori</text>
<text top="701" left="242" width="198" height="10" font="19">antigen. Therefore, we suspect that these two</text>
<text top="701" left="442" width="36" height="10" font="20">H. pylori</text>
<text top="701" left="481" width="37" height="10" font="19">negative</text>
<text top="715" left="76" width="96" height="10" font="19">patients had a former</text>
<text top="715" left="175" width="37" height="10" font="20">H. pylori</text>
<text top="715" left="214" width="265" height="10" font="19">infection, which was eradicated or lost a long time ago. The</text>
<text top="715" left="482" width="37" height="10" font="20">H. pylori</text>
<text top="728" left="77" width="443" height="10" font="19">lysate is probably not sensitive enough to detect this low reactivity. However, a reduced sensitivity</text>
<text top="742" left="77" width="442" height="10" font="19">for CagA and VacA m1 was expected due to the fact that these antigens are virulence factors, and not</text>
<text top="755" left="77" width="80" height="10" font="19">expressed by each</text>
<text top="755" left="159" width="37" height="10" font="20">H. pylori</text>
<text top="755" left="198" width="31" height="10" font="19">strain <a href="">[</a></text>
<text top="755" left="229" width="10" height="10" font="21"><a href="">23</a></text>
<text top="755" left="239" width="6" height="10" font="19"><a href="">].</a></text>
</page>
</pdf2xml>
